C

CVRx Inc
NASDAQ:CVRX

Watchlist Manager
CVRx Inc
NASDAQ:CVRX
Watchlist
Price: 15.3 USD -1.48%
Market Cap: 371.2m USD
Have any thoughts about
CVRx Inc?
Write Note

CVRx Inc
Long-Term Debt

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

CVRx Inc
Long-Term Debt Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Long-Term Debt CAGR 3Y CAGR 5Y CAGR 10Y
C
CVRx Inc
NASDAQ:CVRX
Long-Term Debt
$29.2m
CAGR 3-Years
15%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Becton Dickinson and Co
NYSE:BDX
Long-Term Debt
$17.9B
CAGR 3-Years
2%
CAGR 5-Years
0%
CAGR 10-Years
17%
Boston Scientific Corp
NYSE:BSX
Long-Term Debt
$9.2B
CAGR 3-Years
2%
CAGR 5-Years
-1%
CAGR 10-Years
8%
Stryker Corp
NYSE:SYK
Long-Term Debt
$13.3B
CAGR 3-Years
2%
CAGR 5-Years
11%
CAGR 10-Years
15%
Abbott Laboratories
NYSE:ABT
Long-Term Debt
$13.1B
CAGR 3-Years
-9%
CAGR 5-Years
-6%
CAGR 10-Years
13%
Intuitive Surgical Inc
NASDAQ:ISRG
Long-Term Debt
$0
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

CVRx Inc
Glance View

Market Cap
370.3m USD
Industry
Health Care

CVRx, Inc. develops proprietary active implantable technology to treat high blood pressure and heart failure. The company is headquartered in Minneapolis, Minnesota and currently employs 109 full-time employees. The company went IPO on 2021-06-30. The firm is focused on developing, manufacturing and commercializing minimally invasive neuromodulation solutions for patients with cardiovascular diseases. Its platform technology offers BAROSTIM, designed to control the brain to address the imbalance of the autonomic nervous system (ANS), which causes heart failure (HF) and other cardiovascular diseases. The Company’s product, BAROSTIM NEO, is a neuromodulation device indicated to improve symptoms for patients with heart failure with reduced ejection fraction (HFrEF). BAROSTIM NEO provides baroreflex activation therapy (BAT) by sending imperceptible and persistent electrical pulses to baroreceptors located in the wall of the carotid artery to signal the brain to modulate cardiovascular function. BAROSTIM NEO consists of two implantable components, an implantable pulse generator (IPG) and a stimulation lead.

CVRX Intrinsic Value
11.54 USD
Overvaluation 25%
Intrinsic Value
Price
C

See Also

What is CVRx Inc's Long-Term Debt?
Long-Term Debt
29.2m USD

Based on the financial report for Dec 31, 2023, CVRx Inc's Long-Term Debt amounts to 29.2m USD.

What is CVRx Inc's Long-Term Debt growth rate?
Long-Term Debt CAGR 3Y
15%

Over the last year, the Long-Term Debt growth was 336%. The average annual Long-Term Debt growth rates for CVRx Inc have been 15% over the past three years .

Back to Top